IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with two proprietary, FDA-approved oncology drugs on the market, today announced that it has received $20 million from three institutional investors in a previously announced registered direct offering. The financing was led by Federated Kaufmann Fund, which purchased a majority of the offering.
